Filament Health — SPAC Merger (October 2023)
27 slides from Filament Health's SPAC merger presentation, Oct 2, 2023
Slide 1: Psychedelic Medicines Naturally Derived: Proposed Business Combination with Jupiter Acquisition Corporation
Corporate Presentation - July 2023 Psychedelic Medicines Naturally Derived October 2023 Investor Presentation Proposed Business Combination with Jupiter Acquisition Corporation
Slide 2: Disclaimer
Investor Presentation - October 2023 FILAMENT HEALTH Disclaimer This presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination between Filament Cor
Slide 3: Filament Health Value Pillars
Investor Presentation - October 2023 FILAMENT HEALTH 3 Filament Health Value Pillars ● Botanical drug development platform to create clinical - stage drug candidates ● Exceptional IP benefits from complex botanical API with faster path to clinic and ongoing distribution via early access programs ● M
Slide 4: Summary Transaction Overview
Investor Presentation - October 2023 FILAMENT HEALTH 4 Summary Transaction Overview • Filament Health Corp. (“Filament”) signed a Business Combination Agreement on July 18, 2023, to combine with Jupiter Acquisition Corporation (Nasdaq:JAQC) (“Jupiter”) • Combined company will operate under the same
Slide 5: Detailed Transaction Overview
Investor Presentation - October 2023 FILAMENT HEALTH 5 Detailed Transaction Overview Illustrative Sources & Uses Sources (In USD millions) 15.3 $ Jupiter Cash in Trust 5 176.0 $ Stock Issuance to Filament 8 1.9 $ Cash from Bridge Financing 10 5.0 $ Cash from PIPE 6 198.2 $ Total Sources Uses (In USD
Slide 6: Botanical Drug Overview
Investor Presentation - October 2023 FILAMENT HEALTH ● Defined by the FDA Botanical Drug Guidance (2016) 1 , botanical drugs: ○ Are derived from plant materials, algae, macroscopic fungi, and combinations thereof ○ Have a complex combination of multiple active compounds, rather than one single compo
Slide 7: Botanical Drug Advantages: Intellectual Property
Investor Presentation - October 2023 FILAMENT HEALTH 7 Botanical Drug Advantages 1. Intellectual Property ● Process patents for manufacturing methods (extraction, purification, standardization) ● Small changes in the source material, manufacturing methods, or formulation can cause large changes in t
Slide 8: Botanical Drug Advantages: Efficacy and Fast Track to Clinic
Investor Presentation - October 2023 FILAMENT HEALTH 8 3. Efficacy Benefits and Consumer Preference ● Positive efficacy benefit from several compounds working together (entourage effect) is not possible in synthetics or natural isolates ● Natural drugs have a completely different impurity profile wh
Slide 9: Botanical Drug Advantages Best Leveraged in Psychedelics
Investor Presentation - October 2023 FILAMENT HEALTH Second Generation Psychedelic Compounds: ● While patentable, have unknown safety and efficacy requiring costly and risky preclinical work ● Seek to shorten treatment time; whether this can be accomplished remains to be seen. For now the only real
Slide 10: Currently in FDA Trials: Psychedelic Botanical Drugs
Investor Presentation - October 2023 FILAMENT HEALTH 10 Currently in FDA Trials: Psychedelic Botanical Drugs Technology enables rapid creation of unique, protected drug candidates with fast - track to clinical development Code Primary Compound Route Standardized Dosages R&D Phase I Phase II Target I
Slide 11: Drug Development Focus - Substance Use Disorders
Investor Presentation - October 2023 FILAMENT HEALTH 11 Drug Development Focus - Substance Use Disorders Clear endpoints and significant unmet needs ● Among Americans aged 12 or older in 2021, 8.6% (or 24 million people) had at least one drug use disorder in the past year 1 ● Psychedelics have long
Slide 12: Stimulant Use Disorder Market Opportunity
Investor Presentation - October 2023 FILAMENT HEALTH 1. Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health 2. NCHS Data Brief: Drug Overdose Deaths in the United States, 1999 – 2019 3. Filament - commissioned 3rd Party Re
Slide 13: Opioid Use Disorder Market Opportunity
Investor Presentation - October 2023 FILAMENT HEALTH ● In the latest (2021) national survey, 9.2 million Americans reported opioid misuse of which 5.6 million reported an opioid use disorder (OUD) 1 ● Overdose deaths nearly doubled from 7.4 to 15.5 deaths per 100,000 standard population from 2012 to
Slide 14: Pre-Marketing Authorization Sales
Investor Presentation - October 2023 FILAMENT HEALTH 14 Pre - Marketing Authorization Sales Significant revenue opportunities and potential first - mover advantage in both pharma and non - pharma emerging markets Prescription: Several jurisdictions have enabled pre - marketing authorization distribu
Slide 15: Strategic Out-Licensing Program
Investor Presentation - October 2023 FILAMENT HEALTH Strategic Out - Licensing Program ● Filament Milestone payments are generated with respect to each Phase II and/or III clinical trial conducted 2 ● Marketing authorization milestones are separately triggered in each major jurisdiction 15 Illustrat
Slide 16: Select Customer Contracts
Investor Presentation - October 2023 FILAMENT HEALTH 16 LICENSING Select Customer Contracts Demonstrated history of generating revenue through strategic out - licensing arrangements Commercial Rights? 1 Arrangement Drug Trial Jurisdiction Phase 3 Phase 2 Phase 1 Indication Customer Yes Licensing PEX
Slide 17: Significant Intellectual Property Portfolio
Investor Presentation - October 2023 FILAMENT HEALTH Significant Intellectual Property Portfolio As of September 22 nd , 2023, 20 issued patents and at least 45 additional patent applications believed to create significant barriers to entry ● There are a finite number of ways to extract, purify, and
Slide 18: Enabling a Thriving Research Ecosystem
Investor Presentation - October 2023 FILAMENT HEALTH Enabling a Thriving Research Ecosystem Indication Dosage Drug Phase 3 Phase 2 Phase 1 Sponsor Depression 1mg PEX010 University of Toronto Alcohol Use Disorder 25mg PEX010 Brugmann University Hospital Alcohol Use Disorder 25mg PEX010 Copenhagen U.
Slide 19: Magdalena Biosciences Joint Venture
Investor Presentation - October 2023 FILAMENT HEALTH Magdalena Biosciences Joint Venture 19 (20% ownership) ● Provide funding of US $1.0M on the achievement of defined milestones Value - creating joint venture leveraging Filament’s R&D expertise ● Formed US - based joint venture, Magdalena Bioscienc
Slide 20: Vertically-Integrated Supply Chain
Investor Presentation - October 2023 FILAMENT HEALTH Vertically - Integrated Supply Chain ~3,500 ft 2 GMP - compliant manufacturing, research, and development facility on British Columbia Institute of Technology campus Propagation, extraction, production, distribution, and sale of all natural psyche
Slide 21: Filament Management Team
Investor Presentation - October 2023 FILAMENT HEALTH Filament Management Team Deep experience in botanical extraction, intellectual property, biotech, pharma, commercialization, and capital markets Benjamin Lightburn CEO, Director Co - Founder B.Sc (Physics), MBA Proven entrepreneur and leader speci
Slide 22: Filament Board of Directors
Investor Presentation - October 2023 FILAMENT HEALTH Filament Board of Directors Jon Conlin Director Partner at Fasken Corporate and commercial lawyer specializing in companies in the technology and health sciences sectors including venture capitalists and start - ups Maureen O’Connell Director, Aud
Slide 23: Overview of the Jupiter Acquisition Corporation Team
Investor Presentation - October 2023 FILAMENT HEALTH 23 Overview of the Jupiter Acquisition Corporation Team Jupiter Overview Jupiter is a special purpose acquisition company (“SPAC”) created to enter into a business combination with a company where the management team can make a transformative impa
Slide 24: Selected Clinical Stage Psychedelic Companies Valuation
Investor Presentation - October 2023 FILAMENT HEALTH $27 $68 $117 $216 $343 $547 Source: Filament Management, S&P CapitalIQ, Company Filings; Market data as of 9/28/2023 1. Represents the market capitalizations and enterprise values as of 9/28/2023 2. The valuations listed on this slide reflect valu
Slide 25: Selected Clinical Stage Psychedelic Companies
Investor Presentation - October 2023 FILAMENT HEALTH 25 Selected Clinical Stage Psychedelic Companies (1)(2)(3) NCE = New Chemical Entity Source: Filament Management, S&P CapitalIQ, Company Filings; Market data as of 9/28/2023 1. Represents the market capitalizations and enterprise values as of 9/28
Slide 26: Summary of Risk Factors
Investor Presentation - October 2023 FILAMENT HEALTH The risks listed below are certain of the general risks related to the business of Filament Corp. ("Filament"). This list is not exhaustive and has been prepared solely for the purpose of inclusion in this presentation and not for any other purpos
Slide 27: Glossary
Investor Presentation - October 2023 FILAMENT HEALTH 27 Glossary Active Compounds: Substance formed from two or more elements that exerts a direct physiological effect on a plant, animal or another microorganism Active Metabolite: An agent produced following metabolism of a drug, which has its own t